The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 08, 2024

Filed:

Sep. 02, 2022
Applicant:

Corcept Therapeutics Incorporated, Menlo Park, CA (US);

Inventors:

Stacie Shepherd, Menlo Park, CA (US);

Joseph K. Belanoff, Menlo Park, CA (US);

Assignee:

Corcept Therapeutics Incorporated, Redwood City, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 47/64 (2017.01); A61K 31/337 (2006.01); A61K 31/4745 (2006.01); A61P 15/00 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/643 (2017.08); A61K 31/337 (2013.01); A61K 31/4745 (2013.01); A61P 15/00 (2018.01); A61P 35/00 (2018.01);
Abstract

Methods and compositions for treating cancer (e.g., ovarian, fallopian tube, uterine, cervical, vaginal, vulvar, or peritoneal cancer) are disclosed. The methods include intermittent administration of a glucocorticoid receptor modulator (GRM), such as a non-steroidal GRM (e.g., relacorilant), which may be orally administered, along with a cancer chemotherapy agent (such as, e.g., bevacizumab) to the patient. The GRM may be administered: at intervals separated by at least one day without GRM administration; by a schedule linked to the cancer chemotherapy schedule (e.g., a weekly chemotherapy regimen); on the day of, or the day before, or the day after, chemotherapy administration; by combinations thereof; and/or on other days. Ovarian cancer patients receiving intermittent relacorilant administration along with nab-paclitaxel administration had improved overall survival, improved progression free survival, improved duration of response, and other benefits as compared to patients not receiving relacorilant while receiving nab-paclitaxel.


Find Patent Forward Citations

Loading…